Skip to main content

Table 3 Associations between genetically predicted urate, baseline FEV1 and lung cancer incidence

From: Serum urate and lung cancer: a cohort study and Mendelian randomization using UK Biobank

  Coefficient per 100 µmol serum urate* p value Coefficient per 100 µmol serum urate* p value Incidence change per 10,000 PYs
FEV1 (ml) IRR lung cancer
Overall − 10.5 (− 23 to 2.1) 0.10 0.88 (0.68–1.14) 0.33 − 0.98 (− 2.95 to 1.00)
Never − 12.3 (− 28.5 to 3.9) 0.14 0.88 (0.42–1.85) 0.74 − 0.25 (− 1.76 to 1.26)
Former − 12.0 (− 32.9 to 8.9) 0.26 0.86 (0.59–1.26) 0.43 − 1.36 (− 4.75 to 2.03)
Current 11.0 (− 32.9 to 55.0) 0.62 0.91 (0.61–1.34) 0.62 − 3.40 (− 17.01 to 10.21)
Overall regular − 5.0 (− 28.9 to 18.8) 0.68 0.88 (0.66–1.18) 0.40 − 2.43 (− 8.09 to 3.24)
Light former − 14.3 (− 50.7 to 22.2) 0.44 1.60 (0.69–3.70) 0.27 3.63 (− 2.83 to 10.08)
Heavy former − 17.6 (− 54.0 to 18.8) 0.34 0.68 (0.42–1.10) 0.12 − 6.11 (− 13.73 to 1.52)
Current light 15.9 (− 43.5 to 75.3) 0.60 1.00 (0.54–1.86) 1.00 0.05 (− 23.32 to 23.43)
Current heavy 40.9 (− 37.7 to 119.4) 0.31 0.56 (0.31–1.00) 0.05 − 39.10 (− 78.36 to 0.16)
  1. IRR incidence rate ratio
  2. *Adjusted for sex, age, calendar year, ethnicity (first 40 principal components) and recruitment centre